A. People: Project Leader: Ana Belén Elgoyhen, Ph.D., Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina. Principal Investigators: Clinical Trials • Otosul-Otorrinolaringología, Volta Redonda, Brazil, Andreia Azevedo, M.D. • Otosul-Otorrinolaringología, Volta Redonda, Brazil, Ricardo Figui...

Venture capital groups and big pharma have largely held back from investing in biotech companies focused on regenerative medicine. Will it take a clinical bull's eye to bring venture capitalists and big pharma into the cell therapy arena?

Drug development is time consuming, resource intensive, risky, and heavily regulated. To ensure that it makes the best drug-development decisions, Bayer Pharmaceuticals (Pharma) uses a structured process based on the principles of decision analysis to evaluate the technical feasibility and market potential of its new drugs. In July 1999, the biological products leadership committee composed of ...